Valuation: Glaukos Corporation

Market Cap 14.56B 13.16B 12.15B 11B 20.76B 1,369B 21.38B 146B 57.96B 732B 54.64B 53.47B 2,329B P/E 2026 *
-831x
P/E 2027 * 187x
Enterprise Value 14.41B 13.03B 12.03B 10.89B 20.54B 1,354B 21.16B 144B 57.37B 724B 54.07B 52.92B 2,305B EV / Sales 2026 *
18.5x
EV / Sales 2027 * 14.2x
Free-Float
96.36%
Yield 2026 *
-
Yield 2027 * -
1 day-0.46%
1 week+11.84%
Current month+3.55%
1 month+46.43%
3 months+31.83%
6 months+80.43%
Current year+117.90%
1 week 226.17
Extreme 226.17
249.97
1 month 163.13
Extreme 163.13
255.18
Current year 93.96
Extreme 93.96
255.18
1 year 87.32
Extreme 87.3196
255.18
3 years 59.22
Extreme 59.22
255.18
5 years 33.33
Extreme 33.33
255.18
10 years 23.08
Extreme 23.075
255.18
Manager TitleAgeSince
Chief Executive Officer 65 01/01/2001
Director of Finance/CFO 56 01/04/2022
Director of Finance/CFO 50 05/05/2017
Director TitleAgeSince
Chairman 65 31/12/2021
Director/Board Member 71 01/07/2014
Director/Board Member 57 01/07/2014
Date Insider Type Main position Quantity % Market Cap. Importance
4/11/26 Exercice

Director

7,500 0.0131%
30/10/26 Don

Director

-4,764 0.0083%
30/10/26 Exercice

Executive/Senior Manager

70,374 0.1227%
Change 5-day change 1-year change 3-year change Capi.($)
-0.46%+11.84%+165.66%+306.39% 14.56B
-1.87%-5.59%-16.74%+14.13% 186B
-0.61%-3.67%+5.41%+42.88% 124B
-2.01%-6.77%-14.96%+14.17% 119B
+0.72%-6.42%-43.31%+2.60% 91.43B
-0.14%+2.86%-3.86%+76.84% 66.67B
+0.55%+1.01%+12.28%-8.07% 58.76B
-0.65%+4.07%-2.18%+62.81% 54.99B
-0.68%+6.83%-1.64%+55.26% 49.93B
-5.17%+0.55% - - 35.13B
Average -1.02%-0.59%+11.18%+63.00% 80B
Weighted average by Cap. -1.03%-3.09%-7.20%+32.92%

Financials

2026 *2027 *
Net sales 781M 706M 652M 590M 1.11B 73.38B 1.15B 7.82B 3.11B 39.23B 2.93B 2.87B 125B 1B 907M 838M 758M 1.43B 94.34B 1.47B 10.05B 4B 50.43B 3.77B 3.69B 161B
Net income -17.36M -15.7M -14.49M -13.12M -24.76M -1.63B -25.5M -174M -69.14M -873M -65.17M -63.78M -2.78B 76.26M 68.96M 63.66M 57.62M 109M 7.17B 112M 764M 304M 3.83B 286M 280M 12.2B
Net Debt -149M -135M -125M -113M -213M -14.03B -219M -1.5B -594M -7.5B -560M -548M -23.88B -298M -269M -248M -225M -424M -27.99B -437M -2.98B -1.19B -14.96B -1.12B -1.09B -47.62B
Projected Income Statement - Annual - Glaukos Corporation
Logo Glaukos Corporation
Glaukos Corporation is an ophthalmic pharmaceutical and medical technology company. The Company is focused on developing and commercializing therapies for the treatment of glaucoma, corneal disorders and retinal diseases. Its commercial solutions and development-stage product candidates include procedural pharmaceuticals based on an intracameral drug delivery technology designed to reduce intraocular pressure (IOP) by delivering therapeutic levels of glaucoma medication from inside the eye over an extended period of time; Micro-Invasive Glaucoma Surgery (MIGS) products that primarily involve the insertion of a micro-scale device designed to reduce IOP by restoring the natural aqueous humor outflow pathways for patients suffering from glaucoma; bio-activated pharmaceuticals that are intended to strengthen, stabilize, and reshape the cornea for patients impacted by corneal ectatic disorders such as keratoconus, among others.
Employees
1,094
Date Price Change Volume
12/11/26 USD 246.03 -0.46% 808,479
11/11/26 USD 247.16 +4.64% 915,622
10/11/26 USD 236.19 -1.07% 847,918
09/11/26 USD 238.74 +6.39% 854,095
06/11/26 USD 224.41 +2.01% 1,202,866
Trader
Investor
Global
Quality
ESG MSCI
AAA
MarketScreener Ratings - Glaukos Corporation
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
246.03USD
Average target price
242.46USD
Spread / Average Target
-1.45%
  1. Stock Market
  2. Stocks
  3. GKOS Stock